UY35834A - Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon - Google Patents

Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon

Info

Publication number
UY35834A
UY35834A UY0001035834A UY35834A UY35834A UY 35834 A UY35834 A UY 35834A UY 0001035834 A UY0001035834 A UY 0001035834A UY 35834 A UY35834 A UY 35834A UY 35834 A UY35834 A UY 35834A
Authority
UY
Uruguay
Prior art keywords
piperazinas
caseína
quinasa
pirazolo
epsilon
Prior art date
Application number
UY0001035834A
Other languages
English (en)
Spanish (es)
Inventor
Velaparthi Upender
Chetan Padmakar Darne
Liu Peiying
Mark D Wittman
Bradley C Pearce
Araujo Erika
Dasgupta Bireshwar
Jalathi Surendran Nair
Sakthi Kumaran Janakiraman
Chandrasekhar Reddy Rachamreddy
Mettu Mallikarjuna Rao
Arul Mozhi Selvan Subbiah Karuppiah
Bandreddy Subba Reddy
Nagalakshmi Pulicharla
Rajesh Onkardas Bora
Shilpa Holehatti Maheshwarappa
Selvakumar Kumaravel
Mullick Dibakar
Sistla Ramesh
Original Assignee
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Company Una Corporación Del Estado De Delaware filed Critical Bristol Myers Squibb Company Una Corporación Del Estado De Delaware
Publication of UY35834A publication Critical patent/UY35834A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
UY0001035834A 2013-11-14 2014-11-13 Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon UY35834A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361904116P 2013-11-14 2013-11-14

Publications (1)

Publication Number Publication Date
UY35834A true UY35834A (es) 2015-05-29

Family

ID=51952052

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035834A UY35834A (es) 2013-11-14 2014-11-13 Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon

Country Status (9)

Country Link
US (3) US9598423B2 (enExample)
EP (2) EP3068784B1 (enExample)
JP (2) JP6494622B2 (enExample)
CN (2) CN105916855B (enExample)
AR (1) AR098414A1 (enExample)
ES (2) ES2718218T3 (enExample)
TW (1) TW201605859A (enExample)
UY (1) UY35834A (enExample)
WO (2) WO2015073767A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35834A (es) 2013-11-14 2015-05-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon
US10189843B2 (en) 2014-02-27 2019-01-29 The University Of Tokyo Fused pyrazole derivative having autotaxin inhibitory activity
MA41338B1 (fr) * 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
KR102398439B1 (ko) 2016-03-07 2022-05-16 이난타 파마슈티칼스, 인코포레이티드 B형 간염 항바이러스제
WO2017156071A1 (en) 2016-03-09 2017-09-14 Blade Therapeutics, Inc. Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
EP3458455B1 (en) * 2016-05-20 2021-06-16 F. Hoffmann-La Roche AG Novel pyrazine compounds with oxygen, sulfur and nitrogen linker for the treatment of infectious diseases
AU2017292646A1 (en) 2016-07-05 2019-02-07 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
WO2018011163A1 (en) * 2016-07-14 2018-01-18 F. Hoffmann-La Roche Ag 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
US10934261B2 (en) 2016-09-28 2021-03-02 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
TWI782056B (zh) 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有ｍｇａｔ２抑制活性的縮合環衍生物
KR20200032702A (ko) * 2017-07-27 2020-03-26 지앙수 헨그루이 메디슨 컴퍼니 리미티드 피페라진 헤테로아릴 유도체, 그 제조 방법 및 의약에서 이의 용도
SG11202001685TA (en) 2017-08-28 2020-03-30 Enanta Pharm Inc Hepatitis b antiviral agents
WO2019055877A1 (en) 2017-09-15 2019-03-21 Forma Therapeutics, Inc. TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
JP7212693B2 (ja) 2017-11-01 2023-01-25 ブリストル－マイヤーズ スクイブ カンパニー ファルネソイドｘ受容体モジュレーターとしての架橋二環化合物
US11058678B2 (en) 2018-01-22 2021-07-13 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US10729688B2 (en) * 2018-03-29 2020-08-04 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
CN111295380B (zh) * 2018-06-01 2020-11-20 杭州阿诺生物医药科技有限公司 一种高活性csf1r抑制剂化合物
IL279734B2 (en) 2018-06-29 2024-11-01 Forma Therapeutics Inc Inhibiting creb binding protein (cbp)
TW202024093A (zh) 2018-09-21 2020-07-01 美商安塔製藥公司 作為抗病毒劑之官能化雜環
EP3883570A4 (en) 2018-11-21 2022-07-13 Enanta Pharmaceuticals, Inc. FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS
MX2021008050A (es) 2019-01-11 2021-08-05 Shionogi & Co Derivado de dihidropirazolopirazinona que tiene actividad inhibidora de monoacilglicerol aciltransferasa 2 (mgat2).
CN111484497B (zh) * 2019-01-25 2021-07-02 江苏恒瑞医药股份有限公司 咪唑并[1,5-a]吡嗪类衍生物的可药用盐、晶型及其制备方法
CN111484498B (zh) * 2019-01-25 2021-05-14 江苏恒瑞医药股份有限公司 咪唑并[1,5-a]吡嗪类化合物的晶型及其制备方法
MX2021008929A (es) * 2019-01-25 2021-08-24 Jiangsu Hengrui Medicine Co Forma cristalina de un derivado de 1,2,3-triazolo[1,5-a]pirazinas, y metodo de preparacion para la forma de cristal.
EP3921317B1 (en) 2019-02-07 2023-08-02 Bayer Aktiengesellschaft 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors
TW202102494A (zh) 2019-03-15 2021-01-16 美商弗瑪治療公司 抑制環amp-反應元件-結合蛋白(creb)
WO2020247444A1 (en) 2019-06-03 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
WO2020247561A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
US11472808B2 (en) 2019-06-04 2022-10-18 Enanta Pharmaceuticals, Inc. Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
WO2021007488A1 (en) 2019-07-11 2021-01-14 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2021055425A2 (en) 2019-09-17 2021-03-25 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
WO2022023340A1 (en) 2020-07-29 2022-02-03 Bayer Aktiengesellschaft Substituted heterocyclic compounds and therapeutic uses thereof
WO2022023341A1 (en) 2020-07-29 2022-02-03 Bayer Aktiengesellschaft Substituted 1 h-pyrrolo[3,2-b]pyridin compounds and methods of use thereof
CN114057745A (zh) * 2020-07-29 2022-02-18 江苏恒瑞医药股份有限公司 一种三氮唑并[1,5-a]吡嗪制备方法及其应用
JP2023541465A (ja) * 2020-09-17 2023-10-02 ヤンセン ファーマシューティカ エヌ．ベー． カゼインキナーゼ１デルタモジュレーター
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
WO2022166778A1 (zh) * 2021-02-04 2022-08-11 江苏恒瑞医药股份有限公司 一种衣壳蛋白抑制剂的药物组合物及其制备方法
US20250188075A1 (en) * 2022-01-27 2025-06-12 The Broad Institute, Inc. Substituted heterocyclic csnk1 inhibitors
CA3257905A1 (en) * 2022-06-13 2025-04-24 Shionogi & Co., Ltd. CRYSTAL OF A DIHYDROPYRIDINONE DERIVATIVE OR A SOLVATE THEREOF

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100391958C (zh) * 2001-09-19 2008-06-04 安万特医药股份有限公司 化合物
CN100439367C (zh) * 2003-12-11 2008-12-03 安万特药物公司 作为酪蛋白激酶Iε抑制剂的取代的1H-吡咯并[3,2-b、3,2-c和2,3-c]吡啶-2-甲酰胺以及相关类似物
US20050222171A1 (en) * 2004-01-22 2005-10-06 Guido Bold Organic compounds
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
CN101417999A (zh) 2007-10-25 2009-04-29 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
ES2710701T3 (es) 2008-09-24 2019-04-26 Basf Se Compuestos de pirazol para el control de plagas de invertebrados
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
TW201035102A (en) 2009-03-04 2010-10-01 Gruenethal Gmbh Sulfonylated tetrahydroazolopyrazines and their use as medicinal products
FR2960876B1 (fr) * 2010-06-03 2012-07-27 Sanofi Aventis Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
WO2012117048A1 (en) 2011-03-02 2012-09-07 Lead Discovery Center Gmbh Pharmaceutically active disubstituted triazine derivatives
UY35834A (es) 2013-11-14 2015-05-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon

Also Published As

Publication number Publication date
US20150133428A1 (en) 2015-05-14
CN105916856A (zh) 2016-08-31
ES2744636T3 (es) 2020-02-25
EP3068784A1 (en) 2016-09-21
EP3068784B1 (en) 2019-02-20
WO2015073767A1 (en) 2015-05-21
JP6494624B2 (ja) 2019-04-03
EP3068785A1 (en) 2016-09-21
US9273058B2 (en) 2016-03-01
US20160122358A1 (en) 2016-05-05
ES2718218T3 (es) 2019-06-28
JP2016537369A (ja) 2016-12-01
AR098414A1 (es) 2016-05-26
JP6494622B2 (ja) 2019-04-03
CN105916855A (zh) 2016-08-31
CN105916855B (zh) 2019-03-15
CN105916856B (zh) 2018-09-25
US9598423B2 (en) 2017-03-21
JP2016537366A (ja) 2016-12-01
WO2015073763A1 (en) 2015-05-21
TW201605859A (zh) 2016-02-16
US20160311824A1 (en) 2016-10-27
EP3068785B1 (en) 2019-06-26

Similar Documents

Publication Publication Date Title
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
MX372997B (es) Compuestos de aminopirimidina como inhibidores de jak.
MX374439B (es) Compuesto de piridona como inhibidor de c-met
MX2022002976A (es) Inhibidores selectivos de jak1.
PH12015500064B1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
CR20160035A (es) Inhibidores de bromodominios
NI201800042A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1
EA202090291A3 (ru) Производные бипиразола в качестве ингибиторов jak
CR20150474A (es) Inhibidores de bromodominios tetracíclicos
EA201690848A1 (ru) Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
CR20160456A (es) Compuestos de heteroarilo o arilo bibíclicos fusionados
UY37205A (es) Inhibidores de bromodominios
CO6361936A2 (es) Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasa
MX2016013265A (es) Análogos de compuestos de 4h-pirazolo[1,5-a]bencimidazol como inhibidores parp.
EA201491456A1 (ru) Соединения-ингибиторы raf
SV2017005405A (es) Compuestos y composiciones como inhibidores de quinasa raf
MX2017012295A (es) Derivados formilados n-heterociclicos como inhibidores de fgfr4.
MX2016014939A (es) Derivados de carboxamida.
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
DK3083627T3 (da) [1,2,4]triazol[1,5-a]pyrimidinderivater som protozoiske proteasominhibitorer til behandling af parasitsygdomme, såsom leishmaniasis
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза
AR092772A1 (es) Derivado de 7-azaindol
MY180727A (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzeimer?s disease
CY1119540T1 (el) Υποκατασταθεντα απο γλυκοπυρανοσυλιο παραγωγα ινδολο-ουριας και η χρηση τους ως αναστολεις sglt